[
  {
    "ts": null,
    "headline": "Is BMY's Deep Pipeline the Key to Its Next Growth Phase?",
    "summary": "BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",
    "url": "https://finnhub.io/api/news?id=e30052199250baef2f56947ed670fb7e5683f6ed6f976ba74c3672c512b334a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769091300,
      "headline": "Is BMY's Deep Pipeline the Key to Its Next Growth Phase?",
      "id": 138205782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",
      "url": "https://finnhub.io/api/news?id=e30052199250baef2f56947ed670fb7e5683f6ed6f976ba74c3672c512b334a9"
    }
  },
  {
    "ts": null,
    "headline": "Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer",
    "summary": "PALO ALTO, Calif., January 22, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.",
    "url": "https://finnhub.io/api/news?id=32b6ab271b261015fba29f304f4899541789d4a6204cdf144628a9c1e5252262",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769087100,
      "headline": "Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer",
      "id": 138203897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PALO ALTO, Calif., January 22, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.",
      "url": "https://finnhub.io/api/news?id=32b6ab271b261015fba29f304f4899541789d4a6204cdf144628a9c1e5252262"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?",
    "summary": "The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.",
    "url": "https://finnhub.io/api/news?id=07f298a02d55e4a3373b0148c1b694507a0d06628d45254b12dcd36e765afa47",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769082600,
      "headline": "Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?",
      "id": 138203177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.",
      "url": "https://finnhub.io/api/news?id=07f298a02d55e4a3373b0148c1b694507a0d06628d45254b12dcd36e765afa47"
    }
  },
  {
    "ts": null,
    "headline": "Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality",
    "summary": "The unprecedented changes have led to diminished vaccine usage, hurt the investment case for some biotechs, and created a ‌drag that will likely dent revenues and raise costs for companies in the coming years, 15 investors and analysts told Reuters.",
    "url": "https://finnhub.io/api/news?id=0571fc727062c1215eef3cff0485cf64c28e6812a24e8d6860fac5d13466f7fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769061810,
      "headline": "Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality",
      "id": 138202454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The unprecedented changes have led to diminished vaccine usage, hurt the investment case for some biotechs, and created a ‌drag that will likely dent revenues and raise costs for companies in the coming years, 15 investors and analysts told Reuters.",
      "url": "https://finnhub.io/api/news?id=0571fc727062c1215eef3cff0485cf64c28e6812a24e8d6860fac5d13466f7fe"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Crushes Patent, Pricing Probs",
    "summary": "The company is vying to become the first among its healthcare peers to make $100 billion in annual revenue.",
    "url": "https://finnhub.io/api/news?id=971947ae35deed5c7aaa36c0437223d901199907bef43ba3a8a0a4c84cedaf7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769058060,
      "headline": "Johnson & Johnson Crushes Patent, Pricing Probs",
      "id": 138203277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The company is vying to become the first among its healthcare peers to make $100 billion in annual revenue.",
      "url": "https://finnhub.io/api/news?id=971947ae35deed5c7aaa36c0437223d901199907bef43ba3a8a0a4c84cedaf7d"
    }
  }
]